Abstract: The present invention provides methods for preparing a coated pharmaceutical composition comprising the steps of a) providing a pharmaceutically active agent or a nutraceutical; b) providing a solution or a dispersion of a polyvinyl-based, cellulose-based, acrylate-based, or shellac polymeric coating composition, and mixtures thereof, in a solvent selected from the group consisting of C1-C3 alcohols, acetone, and ethyl acetate; and c) coating the pharmaceutical active agent or nutraceutical from step (a) with the coating composition from step (b) in a fluid bed processor by spraying the coating solution from a top spray position downwardly onto the pharmaceutical active agent or nutraceutical to provide the coated pharmaceutical composition. The polymer from the coating composition is present in the coated pharmaceutical composition in an amount from about 1% w/w to about 15% w/w on a dry weight basis.

Abstract: The present invention provides methods for preparing pharmaceutical resin-complexed granules which are taste-masked or capable of providing modified release of a water-soluble drug comprising the steps of (a) dissolving a water-soluble drug in water to form a solution; and (b) granulating the drug solution from step (a) in the presence of a resin capable of complexing with the drug to form a drug-resin complex. The drug:resin ratio in step (b) is from about 1:10 to about 10:1, respectively, on a weight/weight basis and the water:resin ratio in step (b) is from about 1:1 to about 5:1, respectively, on a weight/weight basis.

Abstract: The present invention provides resilient self-adhering granules which comprise a polysaccharide present in an amount from about 10 wt % to about 90 wt % and a binder having a viscosity from about 5,000 mPa·s to about 250,000 mPa·s present in an amount from about 90 wt % to about 10 wt %, wherein the granule is capable of reversible agglomeration at or below 6,500 kilonewtons/m2. The present invention also provides oral dosage compositions comprising the resilient self-adhering granules and methods for making and using the resilient self-adhering granules.

Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.

Abstract: Rapidly disintegrating oral triptan formulations having superior palatability and methods of making such are provided herein. A rapidly disintegrating oral triptan composition can comprise a triptan compound, a resin, a lubricant, a disintegrant, and a compressible material, where the triptan is admixed with the resin forming a taste-masked triptan composition, which is further admixed with the lubricant, the disintegrant, and the compressible material to form the rapidly disintegrating oral triptan composition.

Abstract: Methods and compositions having resilient, self-adhered granules are disclosed and described. In one embodiment, a resilient, self-adhering granule, which includes a combination of a polysaccharide in an amount of about 10 wt % to about 30 wt %; a sugar alcohol in an amount of about 15 wt % to about 35 wt %; and a binder having a viscosity from about 5000 mPa·s to about 250,000 mPa·s in an amount of from about 10 wt % to about 35 wt %, is capable of low-pressure, reversible agglomeration. In other embodiments, an oral dosage form of such granules and methods of administering said forms are provided.

Abstract: Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

Abstract: Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

Abstract: Modified or extended release formulations containing mesalamine compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved mesalamine formulations such as PENTASA®.

Abstract: A modified release pharmaceutical composition is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the composition has a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters and provides modified release of the pharmaceutical independent of a modified release coating. A method for preparing the composition is also provided.